Flutamide

Chemical formula: C₁₁H₁₁F₃N₂O₃  Molecular mass: 276.212 g/mol  PubChem compound: 3397

Interactions

Flutamide interacts in the following cases:

Medicinal products known to prolong the QT interval, medicinal products able to induce Torsade de pointes

Since androgen deprivation treatment may prolong the QT interval, the concomitant use of Flutamide with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics, etc. should be carefully evaluated.

Alcohol

Concomitant administration of other potentially hepatotoxic drugs should be undertaken only after careful assessment of the benefit and risks. Given the known potential liver and renal toxicities of the product, it is important to avoid excessive consumption of alcohol.

Anticoagulants

Increases in prothrombin time have been reported in patients receiving chronic treatment with oral anticoagulants (e.g. warfarin) following initiation of flutamide monotherapy. Therefore careful monitoring of prothrombin time is recommended and it may be necessary to adjust the dose of anticoagulant if flutamide is administered concomitantly with oral anticoagulants.

LHRH agonists

There have been no interactions between flutamide and leuprorelin; nevertheless, in the combined treatment with flutamide and an LHRH agonist, the possible side effects of each medicinal product must be considered.

Fertility

The influence of flutamide on fertility and the development of the progeny has been studied in rats. Additional teratogenicity studies have been performed in rabbits. The effects were related to the anti-androgenic actions of flutamide. These effects are not relevant to the clinical use of flutamide in the treatment of prostate cancer.

Theophylline

Cases of increased theophylline plasma concentrations have been reported in patients receiving concomitant theophylline and flutamide treatment. Theophylline is primarily metabolised by CYP 1A2 which is the primary enzyme responsible for the conversion of Flutamide to its active agent 2-hydroflutamide.

Impaired renal function

Flutamide should be administered with caution in patients with impaired renal function.

Hepatotoxicity

Flutamide may be hepatotoxic and should be used with caution in patients with pre-existing hepatic dysfunction only after considering the benefits and potential risks.

There have been reports of elevated serum transaminase levels, cholestatic jaundice, hepatic necrosis and hepatic encephalopathy associated with Flutamide treatment. The hepatic effects were usually reversible following discontinuation of flutamide, although cases have been reported of death after severe liver damage linked to the use of flutamide. Hepatotoxicity, which may be fatal, may occur after several weeks or months of therapy. Hepatic function should be monitored regularly before, during and after initiation of Flutamide therapy. Treatment with Flutamide should not be initiated in patients with serum transaminase levels exceeding 2-3 times the upper limit of normal.

Periodic liver function tests must be performed before initiation and during treatment, especially in patients receiving long term treatment with flutamide. Appropriate laboratory liver function tests should also be performed for every patient once a month for the first 4 months and then periodically or when the first sign or symptom of hepatic dysfunction occur (e.g. pruritus, dark urine, persistent anorexia, jaundice, right upper quadrant tenderness or unexplained “flu-like” symptoms).

Patients should be advised to discontinue flutamide therapy and seek medical advice immediately if any symptoms or signs suggestive of hepatotoxicity occur. If the patient presents liver function test results indicative of liver damage, clinical jaundice in the absence of hepatic metastasis confirmed by biopsy, or serum transaminase levels of 2 to 3 times above the normal limits in patients that do not present pathological signs, treatment with flutamide must be suspended.

Cardiovascular disease, thromboembolic events

Periodic sperm counts should be considered in patients receiving chronic treatment with Flutamide who have not received medical or surgical castration. Flutamide administration may lead to elevated plasma testosterone and oestradiol levels in such patients, resulting in fluid retention. In severe cases this can lead to an increased risk of angina and heart failure. Therefore caution should be exercised in the use of Flutamide if cardiac disease is present. It can exacerbate oedema or ankle swelling in patients prone to these conditions.

An increase in oestradiol levels may predispose to thromboembolic events.

It has been reported in the literature that increased cardiovascular risk (myocardial infarction, cardiac insufficiency, sudden cardiac death) and the adverse effects on independent cardiovascular risk factors (serum lipoproteins, insulin sensitivity and obesity) may be linked to androgen deprivation with LHRH analogues in patients with prostate cancer. It must be evaluated whether the benefits of the combined androgen blockade compensate the potential cardiovascular risk in patients with risk factors. Patients treated whose signs or symptoms suggest the development of a cardiovascular disease must be monitored.

Interstitial pneumonitis

There have been cases of interstitial pneumonitis reported in patients undergoing treatment with flutamide. Patients should be monitored for the development of respiratory symptoms such as dyspnoea during the first few weeks of therapy.

Diabetes

A decreased tolerance to glucose has been observed in males in treatment with combined androgen blockade. This may manifest as diabetes or a loss of glycaemic control in patients with pre-existing diabetes. Monitoring of the blood glucose and/or glycosylated haemoglobin (HbA1c) levels must be considered in patients who are in treatment with flutamide in combination with LHRH agonists.

G6PD deficiency

Patients with latent or actual G-6-P deficiency may develop methaemoglobinaemia.

Pregnancy

Flutamide is intended only for use in male patients. Contraceptive measures should be taken during treatment.

Flutamide may cause foetal harm when administered to a pregnant woman. In animal studies, the reproductive toxicity of flutamide was associated with the anti-androgenic activity of this agent. There was decreased 24-hour survival in the offspring of rats treated with flutamide at doses of 30, 100, or 200 mg/kg/day (approximately 3, 9, and 19 times the human dose) during pregnancy. A slight increase in minor variations in the development of the sternebra and vertebra was seen in foetuses of rats at the two higher doses. Feminisation of the males also occurred at the two higher dose levels. There was a decreased survival rate in the offspring of rabbits receiving the highest dose (15 mg/kg/day; equal to 1.4 times the human dose).

No studies have been conducted in pregnant women. Therefore, the possibility that flutamide may cause foetal harm if administered to a pregnant woman must be considered.

Nursing mothers

Flutamide is intended only for use in male patients. Contraceptive measures should be taken during treatment.

No studies have been conducted in lactating women. Therefore, the possibility that flutamide may be present in the breast milk of lactating women, must be considered.

Effects on ability to drive and use machines

No studies on effects on the ability to drive and use machines have been performed with flutamide. Possible undesirable effects such as fatigue, dizziness and confusion have been reported and may interfere with the ability to drive and use machines.

Adverse reactions


Monotherapy

The undesirable effects of flutamide most frequently reported are gynaecomastia and/or breast tenderness, sometimes accompanied by periods of galactorrhoea. These reactions often disappear with the suspension of the treatment or reduction of the dose.

It has been proven that flutamide has a low cardiovascular risk potential, significantly less than that of diethylstilboestrol.

Combined treatment

The undesirable effects most frequently reported during combined treatment of flutamide with an LHRH agonist were hot flushes, reduced libido, erectile dysfunction, diarrhoea, nausea and vomiting. With the exception of diarrhoea, these are known undesirable effects of LHRH agonists alone, with a similar frequency.

The high rate of occurrence of gynaecomastia observed with monotherapy with Flutamide decreased greatly in combined treatment. In clinical trials, no significant difference was observed in the rate of occurrence of gynaecomastia between the placebo group and the group treated with flutamide and LHRH agonists.

The following convention has been utilised for the frequency classification:

Very common - (≥1 in 10)
Common - (≥1 in 100 to <1 in 10)
Uncommon - (≥1 in 1,000 to <1 in 100)
Rare – (≥1 in 10,000 to <1 in 1,000)
Very rare - (<1 in 10,000)
Not known – (cannot be estimated from the available data)

SOCMonotherapyCombination therapy with LHRH analog
Infections and infestations
RareHerpes zoster 
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Very rareNeoplasm of the male breast*  
Blood and lymphatic system disorders
Rare Anaemia, leucopenia, thrombocytopenia
Very rare Haemolytic anaemia, megalocytic anaemia, methaemoglobinaemia, sulfhaemoglobinaemia, macrocytic anaemia
Immune system disorders
RareLupus-like syndrome 
Metabolism and nutrition disorders
CommonIncreased appetite 
RareAnorexiaAnorexia
Very rare Hyperglycaemia, aggravation of diabetes mellitus
Psychiatric disorders
CommonInsomnia 
RareAnxiety, depressionDepression, anxiety
Nervous system disorders
RareDizziness, headacheNumbness, confusion, nervousness, drowsiness
Eye disorders
RareBlurred vision 
Cardiac disorders
RareCardiovascular disorders 
Not knownQT prolongation 
Vascular disorders
Very common Hot flushes
RareHot flushes, hypertension, lymphoedemaHypertension
Not known Thromboembolism
Respiratory, thoracic and mediastinal disorders
RareInterstitial pneumonitis, dyspnoea 
Very rareCoughPulmonary symptoms (e.g. dyspnoea), interstitial lung disease
Gastrointestinal disorders
Very common Diarrhoea, nausea, vomiting
CommonNausea, vomiting, diarrhoea 
RareNon-specific abdominal disorders, constipation, ulcer-like pain, dyspepsia, colitis, upset stomach, heartburnNon-specific abdominal disorders, abdominal pain
Hepatobiliary disorders
CommonHepatitis 
Uncommon Hepatitis
RareLiver function test abnormalitiesHepatic dysfunction, jaundice
Very rare Cholestatic jaundice, hepatic encephalopathy, liver cell necrosis, hepatotoxicity with fatal outcome
Skin and subcutaneous tissue disorders
RareUrticaria, pruritus, ecchymosis, alteration of the hair growth pattern and loss of hair (head) Rash
Very rarePhotosensitivity reactionsPhotosensitivity reactions, erythema, ulcers, bullous eruptions, epidermal necrolysis
Musculoskeletal and connective tissue disorders
RareMuscle crampsNeuromuscular symptoms, reduced bone mineral density, osteoporotic disorders, arthralgia, myalgia
Renal and urinary disorders
Rare Genitourinary tract symptoms, dysuria, changes in urinary frequency, change in urine colour to amber or yellow-green
Reproductive system and breast disorders
Very commonGynaecomastia and/or breast pain, breast tenderness, galactorrhoeaDecreased libido, impotence
Uncommon Gynaecomastia
RareReversible increase of serum testosterone levels, reduced sperm counts, decreased libido 
General disorders and administration site conditions
CommonSomnolence, tiredness 
RareOedema, asthenia, malaise, thirst, chest pain, hot flushes, weaknessOedema, injection site irritation
Investigations
CommonTransient abnormal liver functionChanges in liver function
Rare Elevated blood urea nitrogen (BUN) values, elevated serum creatinine values

* There have been a few cases reported of malignant breast neoplasms in male patients treated with flutamide. One of them consisted of the aggravation of a lump that had been detected previously, three or four months prior to commencing monotherapy with flutamide in a patient with benign prostatic hypertrophy. After the excision, a diagnosis was made of slightly differentiated ductal carcinoma. The other case consisted of gynaecomastia and a lump, observed, respectively, two to six months after the start of monotherapy with flutamide to treat an advanced prostate carcinoma. Nine months after the treatment began, the lump was removed and a moderately differentiated invasive ductal tumour was diagnosed in T4N0M0, G3 state.

The high incidence of gynaecomastia seen with flutamide monotherapy is generally reduced with combination therapy.

Micronodular alterations of the body of breast can uncommonly occur.

An increase in serum testosterone is initially possible during monotherapy with flutamide. In addition, hot flushes and changes in hair character can occur.

Following the marketing of flutamide, cases of acute renal failure, interstitial nephritis, and myocardial ischemia have been reported with frequency unknown.

Cross-check medications

Review your medication to ensure that there are no potentially harmful drug interactions or contraindications.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.